Biotech Values

[drbio45]

Webinar regarding orBec moderated by lead investigator

The webcast is still availeble on replay

Oral beclomethasone dipropionate (orBec®) for Transplant-related
GI GVHD: A Clinical Update

A Live Presentation with Lead Investigator on New Data Published in Blood: The Journal of the American Society of Hematology

An “invitation-only” webinar will review highlights of late-stage clinical data demonstrating a long-term survival benefit with oral beclomethasone dipropionate (orBec®) in the treatment of gastrointestinal Graft-versus-Host disease resulting from allogeneic stem cell or bone marrow transplants, as published in the January 23 online edition of Blood.

A Question and Answer period will follow with the lead investigator and a representative from DOR BioPharma.

When: 1:00 p.m. ET (10:00 a.m. PT)
Tuesday, January 30, 2007

Where: Webinar address: http://www.videonewswire.com/event.asp?id=37602
Password: DOR (all caps)
(Please visit the above web address prior to day of event to register.)

Telephone dial-in: [phone]
Passcode: DOR

Overview: The webinar will feature leading gastroenterologist Dr. David M. Hockenbery, Professor of Medicine at the University of Washington School of Medicine and member of the Clinical Research and Human Biology Divisions at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Hockenbery is also the lead investigator for the oral beclomethasone dipropionate clinical trials.

During the webinar, Dr. Hockenbery will discuss:
§ Clinical data published in Blood including long term survival data
§ Role of orBec® as potential prednisone-sparing therapy for GI GVHD

RSVP: Please RSVP to Heather Ioset:
[e-mail]
[phone] x20

Please feel free to forward this information to your colleagues.